Shots:
- The BTD is based on early and preliminary clinical data involves assessing TAK-994 for the treatment of EDS that may demonstrated substantially improved objective and subjective measurements of daytime wakefulness in NT1 patients
- TAK-994 is being evaluated in an ongoing P-II TAK-994-1501 study while the completed data from study will be presented at a future scientific conference
- TAK-994 (PO) is an investigational orexin agonist. If approved, the therapy will provide a future treatment option targeting orexin 2 receptors underlying NT1
Click here to read full press release/ article | Ref: Businesswire | Image: The Hindu Business Line
The post Takeda’s TAK-994 Receives Breakthrough Therapy Designation for the Treatment of Narcolepsy Type 1 first appeared on PharmaShots.
